ABUS EBITDA | Arbutus Biopharma Corp

Arbutus Biopharma Corp (ABUS) EBITDA

2026-06-30: Basis Reported; EBITDA -$5.95M*; Operating income -$5.96M; Depreciation and amortization $11.00K*.
2026-03-31: Basis Reported; EBITDA $168.92M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$8.65M*; Operating income -$8.66M; Depreciation and amortization $11.00K*.
2025-06-30: Basis Reported; EBITDA $1.50M*; Operating income $1.49M; Depreciation and amortization $11.00K*.

Complete source-backed ebitda history.

Available history: 2018-03-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$5.95M*	-$5.96M	$11.00K*	(m)	(m)	(m)	-$6.02M*	(m)	$2.90M	(m)	$0.00*
2026-03-31	Reported	$168.92M	(m)	(m)	(m)	94.30%	(m)	-$8.11M	(m)	$4.12M	(m)	$0.00
2025-09-30	Reported	-$8.65M*	-$8.66M	$11.00K*	(m)	(m)	$0.00*	-$5.82M*	(m)	$5.78M	(m)	(m)
2025-06-30	Reported	$1.50M*	$1.49M	$11.00K*	(m)	(m)	$0.00*	-$15.75M*	(m)	$5.50M	(m)	(m)
2025-03-31	Reported	-$25.37M	(m)	(m)	(m)	-1438.15%	$0.00	-$13.39M	(m)	$8.96M	(m)	(m)
2024-09-30	Reported	-$21.10M*	-$21.44M	$336.00K*	(m)	(m)	$0.00*	-$20.74M*	(m)	$14.27M	(m)	(m)
2024-06-30	Reported	-$21.23M*	-$21.58M	$356.00K*	(m)	(m)	$1.00K*	-$14.50M*	(m)	$15.55M	(m)	(m)
2024-03-31	Reported	-$19.01M	(m)	(m)	(m)	-1240.73%	$95.00K	-$19.30M	(m)	$15.40M	(m)	(m)
2023-09-30	Reported	-$21.19M*	-$21.56M	$369.00K*	(m)	(m)	$32.00K*	-$21.78M*	(m)	$20.17M	(m)	$0.00
2023-06-30	Reported	-$18.04M*	-$18.39M	$342.00K*	(m)	(m)	$859.00K*	-$19.56M*	(m)	$17.69M	(m)	$0.00
2023-03-31	Reported	-$17.08M	(m)	(m)	(m)	-255.41%	$117.00K	-$27.30M	(m)	$18.27M	(m)	$0.00
2022-09-30	Reported	-$17.47M*	-$17.81M	$343.00K*	(m)	(m)	$91.00K*	-$18.69M*	(m)	$20.05M	(m)	$0.00
2022-06-30	Reported	-$13.73M*	-$14.11M	$383.00K*	(m)	(m)	$212.00K*	-$20.29M*	(m)	$22.94M	(m)	$0.00
2022-03-31	Reported	-$10.58M	(m)	(m)	(m)	-84.10%	$75.00K	$20.62M	(m)	$18.46M	(m)	$4.44M
2021-09-30	Reported	-$17.96M*	-$18.41M	$447.00K*	(m)	(m)	$20.00K*	-$16.04M*	(m)	$16.71M	(m)	$0.00
2021-06-30	Reported	-$18.21M*	-$18.64M	$436.00K*	(m)	(m)	$632.00K*	-$14.01M*	(m)	$15.80M	(m)	$0.00
2021-03-31	Reported	-$15.23M	(m)	(m)	(m)	-720.92%	$99.00K	-$17.88M	(m)	$13.78M	(m)	$0.00
2020-09-30	Reported	-$14.73M*	-$15.22M	$490.00K*	(m)	(m)	$11.00K*	-$12.17M*	(m)	$12.06M	(m)	$0.00
2020-06-30	Reported	-$12.64M*	-$13.14M	$501.00K*	(m)	(m)	$66.00K*	-$8.80M*	(m)	$10.46M	(m)	$0.00
2020-03-31	Reported	-$12.65M	(m)	(m)	(m)	-848.22%	$0.00	-$15.45M	(m)	$10.42M	(m)	$0.00
2019-12-31	Reported	(m)	-$13.09M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$90.52M	(m)	(m)	(m)	-2957.14%	$255.00K	-$23.47M	(m)	$17.73M	(m)	-$12.66M
2019-06-30	Reported	-$20.14M	(m)	(m)	(m)	-3084.23%	$240.00K	-$17.61M	(m)	$12.74M	(m)	$0.00
2019-03-31	Reported	-$18.69M	(m)	(m)	(m)	-2752.14%	$31.00K	-$16.58M	(m)	$14.71M	(m)	$0.00
2018-12-31	Reported	(m)	-$16.90M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$31.93M	(m)	(m)	(m)	-2011.91%	$237.00K	-$13.20M	(m)	$16.57M	(m)	-$4.28M
2018-06-30	Reported	-$21.47M	(m)	(m)	(m)	-1725.72%	$425.00K	-$17.62M	(m)	$16.36M	(m)	(m)
2018-03-31	Reported	-$17.8M	(m)	(m)	(m)	-1239.76%	$248.00K	-$19.97M	(m)	$13.95M	(m)	(m)
2017-12-31	Reported	(m)	-$60.25M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	(m)	-$12.90M	(m)	(m)	(m)	$538.00K	-$15.68M	(m)	$15.54M	(m)	$0.00
2017-06-30	Reported	(m)	-$19.48M	(m)	(m)	(m)	$3.12M	-$5.08M	(m)	$15.45M	(m)	$0.00
2017-03-31	Reported	(m)	-$18.30M	(m)	(m)	(m)	$3.42M	-$17.54M	(m)	$13.87M	(m)	(m)
2016-12-31	Reported	(m)	-$257.44M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	(m)	-$18.98M	(m)	(m)	(m)	$168.00K	-$14.71M	(m)	$15.74M	(m)	$0.00
2016-06-30	Reported	(m)	-$195.25M	(m)	(m)	(m)	$954.00K	-$16.80M	(m)	$15.21M	(m)	-$64.86M
2016-03-31	Reported	(m)	-$19.98M	(m)	(m)	(m)	$276.00K	-$11.55M	(m)	$13.14M	(m)	(m)
2015-12-31	Reported	(m)	-$11.76M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	(m)	-$58.14M	(m)	(m)	(m)	$589.00K	-$2.53M	(m)	$16.35M	(m)	-$15.20M
2015-06-30	Reported	(m)	-$14.42M	(m)	(m)	(m)	$383.00K	-$16.67M	(m)	$9.69M	(m)	$0.00
2015-03-31	Reported	(m)	-$18.01M	(m)	(m)	(m)	$141.00K	-$17.84M	(m)	$10.56M	(m)	(m)
2014-12-31	Reported	(m)	-$10.75M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	(m)	-$6.84M	(m)	(m)	(m)	$152.00K	-$6.72M	(m)	$9.31M	(m)	$0.00
2014-06-30	Reported	(m)	-$9.42M	(m)	(m)	(m)	$246.00K	-$8.01M	(m)	$9.30M	(m)	(m)
2014-03-31	Reported	(m)	-$5.96M	(m)	(m)	(m)	$335.00K	$9.15M	(m)	$8.20M	(m)	(m)
2013-12-31	Reported	(m)	-$2.44M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	(m)	-$3.65M	(m)	(m)	(m)	$120.00K*	-$3.67M*	(m)	$5.51M	(m)	(m)
2013-06-30	Reported	(m)	-$3.07M	(m)	(m)	(m)	$120.00K	-$3.67M	(m)	$4.91M	(m)	(m)
2013-03-31	Reported	(m)	-$2.99M	(m)	(m)	(m)	$201.00K	-$2.84M	(m)	$4.07M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$38.16M	(m)	(m)	(m)	$0.00	-$39.64M	(m)	$25.24M	(m)	$0.00
2024-12-31	Reported	(m)	-$76.32M	(m)	(m)	(m)	$182.00K	-$64.85M	(m)	$54.04M	(m)	$0.00
2023-12-31	Reported	(m)	-$78.10M	(m)	(m)	(m)	$1.01M	-$85.94M	(m)	$73.70M	(m)	$0.00
2022-12-31	Reported	(m)	-$65.46M	(m)	(m)	(m)	$512.00K	-$35.36M	(m)	$84.41M	(m)	$4.44M
2021-12-31	Reported	(m)	-$73.52M	(m)	(m)	(m)	$809.00K	-$67.53M	(m)	$65.50M	(m)	$0.00
2020-12-31	Reported	(m)	-$57.81M	(m)	(m)	(m)	$229.00K	-$51.44M	(m)	$49.34M	(m)	$0.00
2020-09-30	Rolling	(m)	-$54.59M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$130.40M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$137.90M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	(m)	-$143.90M	(m)	(m)	(m)	$589.00K	-$71.01M	(m)	$57.60M	(m)	-$12.66M
2019-12-31	Rolling	(m)	-$143.95M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$147.77M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$89.17M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$90.57M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	(m)	-$89.78M	(m)	(m)	(m)	$1.14M	-$67.87M	(m)	$57.93M	(m)	-$4.28M
2018-12-31	Rolling	(m)	-$89.78M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$133.13M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$113.60M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$111.04M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	(m)	-$110.93M	(m)	(m)	(m)	$7.26M	-$48.64M	(m)	$62.68M	(m)	-$24.32M
2017-12-31	Rolling	(m)	-$110.93M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Rolling	(m)	-$308.12M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Rolling	(m)	-$314.20M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-03-31	Rolling	(m)	-$489.96M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	(m)	-$491.64M	(m)	(m)	(m)	$4.00M	-$57.88M	(m)	$61.25M	(m)	-$105.00M
2016-12-31	Rolling	(m)	-$491.64M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Rolling	(m)	-$245.96M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-06-30	Rolling	(m)	-$285.12M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-03-31	Rolling	(m)	-$104.29M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	(m)	-$103.92M	(m)	(m)	(m)	$2.29M	-$56.38M	(m)	$51.51M	(m)	-$16.18M
2015-12-31	Rolling	(m)	-$102.32M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Rolling	(m)	-$101.31M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-06-30	Rolling	(m)	-$50.02M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-03-31	Rolling	(m)	-$45.02M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	(m)	-$33.43M	(m)	(m)	(m)	$1.06M	-$12.42M	(m)	$38.71M	(m)	$0.00
2014-12-31	Rolling	(m)	-$32.97M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Rolling	(m)	-$24.66M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-06-30	Rolling	(m)	-$21.47M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-03-31	Rolling	(m)	-$15.12M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-12-31	Reported	(m)	-$12.15M	(m)	(m)	(m)	$725.00K	-$6.74M	(m)	$21.46M	(m)	$0.00
2013-12-31	Rolling	(m)	-$12.15M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-12-31	Reported	(m)	-12.92M CAD	(m)	(m)	(m)	14.82K CAD	33.10M CAD	(m)	18.03M CAD	(m)	(m)
2012-12-31	Reported	(m)	-$12.95M	(m)	(m)	(m)	$15.00K	$32.91M	(m)	$18.04M	(m)	(m)
2011-12-31	Reported	(m)	-10.54M CAD	(m)	(m)	(m)	59.67K CAD	-7.68M CAD	(m)	19.90M CAD	(m)	(m)
2011-12-31	Reported	(m)	-$10.69M	(m)	(m)	(m)	$60.38K	-$7.83M	(m)	$20.13M	(m)	(m)
2010-12-31	Reported	(m)	-12.52M CAD	(m)	(m)	(m)	830.95K CAD	-11.25M CAD	(m)	22.13M CAD	(m)	(m)
2009-12-31	Reported	(m)	-8.48M CAD	(m)	(m)	(m)	1.70M CAD	-5.53M CAD	(m)	17.76M CAD	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Kura Oncology, Inc. (KURA)	United States	$0.967B	-3.29
Jade Biosciences, Inc. (JBIO)	United States	$0.936B	-9.21
Corvus Pharmaceuticals, Inc. (CRVS)	United States	$0.994B	-23.25
Janux Therapeutics, Inc. (JANX)	United States	$1.019B	-9.15
Pacira BioSciences, Inc. (PCRX)	United States	$1.020B	69.03
Apnimed, Inc. (APMD)	United States	$0.899B
MoonLake Immunotherapeutics (MLTX)	Switzerland	$1.031B	-5.43
RIGEL PHARMACEUTICALS INC (RIGL)	United States	$0.893B	2.25
Savara Inc (SVRA)	United States	$1.044B	-9.10
Theravance Biopharma, Inc. (TBPH)		$0.885B	16.40